PLX

Protalix BioTherapeutics, Inc.

$2.32 +0.02 (+0.87%) At close · Jul 2

Market Cap

$186.93M

80,571,642

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-05-13	Protalix Biotherapeutics First Quarter 2026 Financial and Business Results Conference Call	Conference
2026-03-18	Protalix BioTherapeutics Fiscal Year 2025 Financial and Business Results Conference Call	Conference
2025-11-13	Protalix Biotherapeutics Third Quarter 2025 Financial and Business Results Conference Call	Conference
2025-09-16	Q3 Investor Summit	Event
2025-09-08	H.C. Wainwright 27th Annual Global Investment Conference	Conference
2025-08-14	Protalix Biotherapeutics Second Quarter 2025 Financial and Business Results Conference Call	Conference
2025-05-20	3rd Annual H.C. Wainwright BioConnect Investor Conference	Conference
2025-05-09	Protalix Biotherapeutics First Quarter 2025 Financial and Business Results Conference Call	Conference
2025-03-25	iAccess Alpha Virtual Best Ideas Spring Conference 2025	Conference
2025-03-18	Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting	Presentation
2025-03-17	Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call	Conference
2025-01-23	Protalix Therapeutics’ CEO, Dror Bashan, Interviewed by Proactive	Event
2024-11-14	Protalix Third Quarter 2024 Financial and Business Results Conference Call	Conference
2024-09-19	Protalix BioTherapeutics to Present at the Life Sciences Investor Forum	Event
2024-09-11	Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference	Conference
2024-08-14	Protalix Second Quarter 2024 Financial and Business Results Conference Call	Conference
2024-06-26	In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout	Presentation
2023-08-09	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference	Conference

Key facts CIK 1006281 CUSIP 74365A309 Visit website